
Myelodysplastic syndrome is a group of cancers that prevents hematopoietic stem cells from developing into healthy blood cells. Without enough healthy blood cells, people risk developing dangerous illnesses such as anemia, frequent infections, and uncontrollable bleeding. Some patients with MDS may develop acute myeloid leukaemia (AML).
Myelodysplastic Syndrome (MDS) should be treated as soon as possible to prevent it from progressing to acute myeloid leukaemia (AML), relieve symptoms such as fatigue and anaemia, and improve general health. Early intervention enhances the efficacy of chemotherapy and stem cell transplants, improving outcomes. It also helps to reduce life-threatening complications such as infections and bleeding, which improves the prognosis and survival rates. Therefore, timely treatment is critical for effectively controlling MDS and giving patients a better long-term outlook.
People with myelodysplastic syndromes may not exhibit signs and symptoms at first.
Myelodysplastic syndromes could cause:
The World Health Organization classifies myelodysplastic syndromes into subcategories based on the kind of blood cells involved (red cells, white cells, and platelets).
The myelodysplastic syndrome has several subtypes, including:
Causes
Risk Factors
The following factors can raise your risk of myelodysplastic syndromes:
Complications
Myelodysplastic syndromes can have the following complications:
Chemotherapy: Healthcare practitioners may administer the same chemotherapy used to treat AML. It uses medications to eliminate cancer cells and inhibit tumour growth.
Cost Start From USD 600 - USD 700Explore Options
Immunosuppressive therapy: Providers may utilise this medication for some MDS subtypes. Immunosuppressive medication reduces overactive immune systems, reducing the need for transfusions.
Cost Start From USD 3000 - USD 5000Explore Options
Bone Marrow Transplant: A bone marrow transplant, also known as a stem cell transplant, is the only treatment that can cure myelodysplastic disorders.
Cost Start From USD 25000 - USD 35000Explore Options
Rehabilitation for Hepatocellular Carcinoma (HCC) is an essential component of the rehabilitation process and enhancing quality of life, particularly following surgery, liver transplantation, or other treatments. Here are some essential rehabilitation choices for HCC patients:
MediGence can assist and guide you in selecting the best physician and medical facility for your care.
Treatment for myelodysplastic syndromes may include medications such as:









Amroha, India
Onco Care Cancer Hospital is one of the Top Cancer Treatment Centres in India focused on delivering the best and most affordable treatment for cancer patients with superior quality of care, and the latest treatment options. Chemotherapy, radiation, immunotherapy, and targeted treatment are among the available therapies in the hospital complemented by modern technological and equipment systems.
Both oncologists, surgeons, nursing personnel as well as other staff members, all contribute to discussions and come up with individualized treatment plans for patients. Realizing that traveling abroad for treatment is a tough decision for a family, Onco Care is dedicated to research and innovation as well as trying to deliver the best care now and in the future. Their interventions are to deliver medical and emotional needs and to give ‘a home of hope’ for every individual patient.

Delhi, India

Gurgaon, India
Opinion & Option
We submit the most accurate opinion and options from one or more countries for your review
Consult Privately
Consult with a certified specialist privately on our telemedicine platform even before you decide to travel
Logistics
We handle flights, visas, transfers, and accommodation—so you can focus on your health.
Recovery
Our In-house rehabilitation service packages to better your recovery and treatment outcome
Here are some of the reasons for choosing India:
MDS patients' life expectancy varies according to their subtype, overall health, and response to treatment. Patients with low-risk MDS can live for many years, whereas those with high-risk MDS may develop acute leukaemia, lowering life expectancy. Regular monitoring and treatment can lead to better outcomes.
MDS and leukaemia involve the bone marrow and blood cells, but MDS is a disorder in which the bone marrow generates abnormal cells. In contrast, leukaemia is characterised by the fast, uncontrolled proliferation of defective blood cells. MDS is sometimes thought to be a precursor to leukaemia since it can progress to acute myeloid leukaemia (AML) in some circumstances; however, the two illnesses are separate.
While most cases of MDS are not inherited, specific gene changes can raise the chance of getting the disease. In rare situations, MDS can be inherited as part of a genetic condition, such as Fanconi anaemia. You should speak with a genetic counsellor if you have a family history of blood diseases.
Yes, MDS is treatable, but treatment efficacy is determined by several factors, including the patient's age, overall health, and MDS subtype. Treatment aims to alleviate symptoms, boost blood cell counts, and prevent leukaemia from developing. In India, therapies include supportive care, chemotherapy, immunosuppressive therapy, and bone marrow/stem cell transplants.
Chemotherapy is commonly used to treat high-risk MDS or instances that develop to acute myeloid leukaemia. Chemotherapy medications kill abnormal cells in the bone marrow and restore normal blood cell production. In India, chemotherapy for MDS is provided in big cancer hospitals, where professionals personalise treatment plans.
Many MDS patients can lead very normal lives with proper care. However, symptoms such as exhaustion, recurrent infections, and the need for blood transfusions can influence one's life. Patients can typically retain a high quality of life by receiving therapies such as blood transfusions, medicines, and stem cell transplants.
India is conducting ongoing research and clinical trials to develop new medicines for MDS, such as innovative medications, immunotherapies, and targeted treatments. Some novel medicines aim to increase survival rates and lower the likelihood of MDS progressing to leukemia. Patients can discuss these alternatives with their doctor to learn about new treatments.